Testosterone Cypionate Half-Life Explained: Why Injection Frequency Matters

If you are researching testosterone cypionate through Hemi Pharma UK, one of the first technical details you will encounter is the testosterone cypionate half-life. This single pharmacokinetic property determines how often you need to inject, how stable your blood levels remain between doses, and whether you spend your weeks feeling consistent or riding a hormonal rollercoaster. Understanding it properly is not optional. It is the foundation of every sensible injection protocol, and getting it wrong is the most common reason new users feel worse than they expected.

Key Takeaways

  • Testosterone cypionate has an elimination half-life of approximately 8 days when injected intramuscularly, meaning half of the administered dose remains active in your system after one week.
  • Biweekly (every 14 days) injection schedules create wide peak-to-trough fluctuations that can cause mood swings, energy dips, and increased side effects. Weekly or twice-weekly protocols produce significantly more stable serum levels.
  • The 8-day half-life is longer than testosterone enanthate (approximately 4.5 to 7 days) and considerably longer than testosterone propionate (approximately 2 days), making cypionate one of the most practical esters for consistent self-administration.
  • Body composition, injection site, carrier oil, and individual metabolism all influence how quickly you clear testosterone cypionate, which is why blood work should guide your protocol rather than generic dosing charts.
  • Subcutaneous injection of testosterone cypionate produces more stable serum levels with less peak-to-trough variation compared to intramuscular injection at the same dose and frequency.

What Does Half-Life Actually Mean for Testosterone Cypionate?

Half-life is the time it takes for the concentration of a drug in your blood to fall to exactly half of its peak value. For testosterone cypionate 200mg, the FDA-approved prescribing information for Depo-Testosterone states that the elimination half-life is approximately 8 days when administered via intramuscular injection. This figure comes from the pharmacokinetic profile of the cypionate ester itself, which is an eight-carbon side chain (cyclopentylpropionate) bonded to the testosterone molecule at the 17-beta position.

Here is why the ester matters so much. Unmodified testosterone, if injected directly, has a half-life of roughly 10 to 100 minutes. It would be metabolised almost immediately, making it clinically useless for replacement therapy. The cypionate ester changes this entirely. When you inject testosterone cypionate dissolved in oil (usually cottonseed oil), the oil forms a depot in the muscle tissue. The esterified testosterone slowly diffuses out of that depot into surrounding interstitial fluid. Once it reaches the bloodstream, ubiquitous esterase enzymes cleave the cypionate chain, releasing free, bioactive testosterone. The rate at which the ester exits the depot is what governs the effective half-life.

A population pharmacokinetic study of 31 healthy men receiving weekly testosterone cypionate injections confirmed that a linear one-compartment model with first-order absorption best describes the concentration-time profile. The study found population clearance estimates of 2.6 kL/day and a volume of distribution of 14.4 kL, with body weight and albumin levels identified as significant covariates. In practical terms, this means that your size and protein binding capacity genuinely influence how quickly you process each dose.

How Long Does Testosterone Cypionate Stay in Your System?

The 8-day half-life does not mean that testosterone cypionate is gone from your body after 8 days. It means that after 8 days, approximately half remains. After another 8 days, a quarter remains, and so on. Complete elimination to negligible levels typically takes 5 to 6 half-lives, which for testosterone cypionate equates to roughly 40 to 48 days after your final injection.

This has direct implications for anyone thinking about post-cycle therapy, blood work timing, or switching compounds. If you are planning PCT after a testosterone cypionate cycle, starting a SERM like tamoxifen or clomiphene too early means the exogenous testosterone still circulating will suppress your HPTA, undermining the recovery stimulus.

The following table illustrates the approximate concentration decline after a single 200mg intramuscular injection, based on the 8-day half-life and a peak of approximately 1,100 ng/dL reached around days 4 to 5.

Days After Injection Approximate Remaining Dose Estimated Serum Testosterone Clinical Significance
0 (injection day) 200mg Rising Ester entering bloodstream from depot
2 to 5 ~170 to 180mg ~900 to 1,100 ng/dL (peak) Supraphysiological in many men
8 ~100mg ~550 to 600 ng/dL Mid-range physiological
14 ~50mg ~250 to 350 ng/dL Approaching hypogonadal threshold
16 ~40mg ~200 to 280 ng/dL Below physiological range for many men
24 ~12.5mg ~100 to 150 ng/dL Clearly hypogonadal
40+ Trace Near baseline Effectively cleared

These figures are approximations based on published pharmacokinetic data and will vary between individuals. The key takeaway is the sheer magnitude of the decline: from over 1,000 ng/dL at peak to potentially below 300 ng/dL by day 14. That is the fundamental problem with infrequent dosing schedules.

Why Does the 8-Day Half-Life Make Injection Frequency So Important?

The relationship between half-life and injection frequency is arguably the most misunderstood aspect of testosterone replacement therapy. Many prescribers, particularly within the NHS, still default to fortnightly (every 14 days) injection protocols for testosterone cypionate or enanthate. The pharmacokinetics make it clear why this creates problems.

What Happens with Biweekly (Every 14 Days) Injections?

A biweekly injection of 200mg testosterone cypionate produces a serum testosterone curve that swings dramatically. Within 2 to 5 days, levels spike to supraphysiological concentrations, often exceeding 1,000 ng/dL. By day 13 to 14, levels have dropped back to baseline or even into the hypogonadal range. A comparative study of 263 men receiving either 100mg weekly or 200mg biweekly intramuscular testosterone found that while both regimens achieved similar average testosterone levels, the 200mg biweekly group was significantly more likely to develop erythrocytosis (haematocrit above 54%). Specifically, 7.8% of the biweekly group exceeded the 54% threshold compared to just 1.0% of the weekly group. The higher peak concentrations drive greater erythropoietin stimulation, which in turn drives excessive red blood cell production.

Beyond the haematological risk, the subjective experience matters. Many men on biweekly protocols describe a pattern of feeling excellent for the first 4 to 5 days, then experiencing a gradual decline in energy, libido, and mood over the second week. This is not psychological. It is a direct consequence of the pharmacokinetic curve. When your testosterone levels swing from over 1,000 ng/dL to below 300 ng/dL every fortnight, your body never reaches a hormonal steady state.

What Happens with Weekly Injections?

Splitting the same total dose into weekly administrations (100mg every 7 days instead of 200mg every 14 days) produces a dramatically different pharmacokinetic profile. The peaks are lower, the troughs are higher, and the overall fluctuation is greatly reduced. Within 4 to 6 weeks of weekly injections, your serum testosterone reaches a genuine steady state, where each new injection is administered before the previous dose has fully cleared.

This is where the 8-day half-life actually works in your favour. Because the half-life slightly exceeds the 7-day injection interval, each weekly dose adds to a small residual amount from the previous injection. The result is accumulation to a stable, predictable trough level, typically between 500 and 700 ng/dL for most men on 100mg weekly, depending on individual clearance rates.

The same comparative study found that weekly dosing produced lower erythrocytosis risk despite delivering the same total monthly dose of testosterone. This finding aligns with the pharmacokinetic principle that lower peak concentrations reduce dose-dependent side effects, even when average exposure remains the same.

Is Twice-Weekly Injection Better for Stability?

For users who are particularly sensitive to fluctuations, or those who aromatise readily and want tighter oestradiol control, twice-weekly injection (for example, 50mg every 3.5 days) further flattens the curve. The peak-to-trough variation on a twice-weekly protocol is estimated to be roughly 40% smaller than on a weekly protocol. Some users report that the difference in how they feel day to day is noticeable, particularly regarding mood stability and water retention.

Whether twice-weekly is necessary depends on the individual. If your blood work shows stable levels and you feel consistent on weekly injections, there is no pharmacological reason to increase the injection burden. The goal is stability, not frequency for its own sake. Using a product like Hemi Pharma Testosterone Cypionate 200mg, which is independently batch-tested by Janoshik Analytical, means you can trust that each dose contains exactly what the label states, removing one variable from your protocol.

How Does Testosterone Cypionate Compare to Other Esters by Half-Life?

The comparison between testosterone cypionate and testosterone enanthate is the most common question in this area, because both esters are frequently used for TRT and cycles. The difference in half-life is real but often overstated in practical terms.

Testosterone Ester Ester Carbon Chain Approximate Half-Life Typical Injection Frequency Common UK Use
Testosterone Propionate 3 carbons 2 to 3 days Every other day Short cycles, competition prep
Testosterone Enanthate 7 carbons 4.5 to 7 days Weekly or twice weekly TRT, cycles
Testosterone Cypionate 8 carbons ~8 days Weekly or twice weekly TRT, cycles
Sustanon 250 (blend) Mixed (3 to 11) Variable (longest ester ~15 days) Every 7 to 21 days NHS TRT, cycles
Testosterone Undecanoate (Nebido) 11 carbons ~21 to 34 days Every 10 to 14 weeks NHS TRT

The general principle is straightforward: longer carbon chains create greater lipophilicity (fat solubility), which slows diffusion from the intramuscular depot and extends the effective half-life. Testosterone cypionate’s eight-carbon ester sits in a pharmacokinetic sweet spot. It is long enough to support convenient weekly injection without excessive peak-to-trough swings, yet short enough to allow meaningful dose adjustments within a few weeks. Compare this to Nebido, where a single injection lasts months but dose titration is extremely slow and the troughs before each injection can leave men symptomatic for weeks.

A 2017 study confirmed that the pharmacokinetic difference between cypionate and enanthate, while real, is clinically insignificant for most practical purposes. Both esters are considered interchangeable at equivalent doses and frequencies in the published literature.

Does Subcutaneous Injection Change the Half-Life of Testosterone Cypionate?

Subcutaneous (SC) injection of testosterone cypionate has become increasingly popular among TRT users in the UK, and the pharmacokinetic data is encouraging. A pharmacokinetic study of 11 patients receiving weekly subcutaneous testosterone cypionate measured free and total testosterone at eight time points across a single dosing interval. The results showed that mean serum levels remained stable and within the normal male range throughout the entire 7-day period between injections. The mean total testosterone across the seven inter-injection samples was 627 ng/dL, with minimal variation from day to day.

This stability is likely related to the different absorption dynamics of subcutaneous tissue compared to muscle. Subcutaneous fat has lower vascularity than skeletal muscle, meaning the depot releases testosterone cypionate more slowly and more evenly. The practical effect is a blunted peak and an elevated trough, which is exactly what most TRT users want.

A larger retrospective study of 63 patients receiving weekly subcutaneous testosterone cypionate confirmed that therapeutic male-range serum levels were achieved in all participants at doses ranging from 50 to 150mg weekly. Minor local reactions (small lumps at the injection site) were reported in 9 out of 63 patients but were transient. Importantly, all patients who had previously used intramuscular injections preferred the subcutaneous route.

While the terminal elimination half-life of the ester itself does not fundamentally change with injection route, the absorption half-life does. Subcutaneous administration effectively extends the absorption phase, producing a pharmacokinetic profile that behaves as though the half-life were slightly longer. For users who want maximum stability from their testosterone cypionate protocol, subcutaneous injection is worth discussing with your prescriber.

How Should You Time Blood Work Around the Testosterone Cypionate Half-Life?

Blood work timing is one of the most common sources of confusion, and the half-life provides the answer. The British Society for Sexual Medicine (BSSM) and the Endocrine Society both recommend measuring serum testosterone at trough, which means the morning before your next injection, when your levels are at their lowest point in the dosing cycle.

Why trough and not peak? Because trough values tell you whether your lowest level still falls within the therapeutic range. If your trough is adequate (generally above 15 nmol/L or approximately 430 ng/dL for TRT), then your levels throughout the rest of the week are necessarily higher and almost certainly sufficient. If your trough is too low, you may need a dose increase or a frequency change. Measuring at peak (1 to 3 days post-injection) tells you very little of clinical value, because the peak is always going to be the highest point on the curve.

For men injecting weekly, trough bloods should be drawn on day 7, ideally in the morning before that day’s injection. For twice-weekly protocols, draw on the morning of day 3 or 4 after the last injection, before the next dose. Consistency in timing is more important than perfection: always draw at the same point in your cycle so that your results are comparable over time.

It is also worth checking haematocrit and haemoglobin at each blood draw, given the established link between testosterone dose, peak levels, and erythrocytosis. If your haematocrit is creeping above 52%, consider increasing injection frequency (to lower peaks) before reducing the total dose, as this preserves the therapeutic benefit while addressing the haematological risk.

What Factors Can Affect Your Individual Testosterone Cypionate Half-Life?

While the population average half-life is approximately 8 days, individual variation is real and clinically meaningful. The pharmacokinetic modelling study by Bi et al. (2018) identified several covariates that significantly influence testosterone clearance.

Body Composition and Weight

Body weight was identified as a significant covariate in the population PK model. Men with higher body mass tend to have a larger volume of distribution, which can effectively extend the apparent half-life. However, men with higher body fat percentages also have greater aromatase activity, which converts testosterone to oestradiol more rapidly. This does not change the half-life of the ester per se, but it does change how much active testosterone versus oestradiol you produce from each dose. Managing oestradiol with an aromatase inhibitor like anastrozole may be necessary for some men, but should be guided by blood work showing elevated oestradiol with symptoms, not used prophylactically.

Injection Site and Technique

The rate of absorption from an intramuscular depot depends partly on local blood flow. The gluteal and vastus lateralis (outer thigh) muscles are the standard injection sites for testosterone cypionate, and both provide reliable absorption. Injecting into a muscle with greater blood flow can slightly increase the initial absorption rate, producing a marginally higher peak. Conversely, poor injection technique, such as injecting too superficially or into scar tissue from repeated injections at the same site, can create erratic absorption patterns. Rotating injection sites is standard practice for this reason.

Carrier Oil

Testosterone cypionate is typically dissolved in cottonseed oil (as in the branded Depo-Testosterone) or in other carrier oils such as grapeseed oil or MCT (medium-chain triglyceride) oil. The viscosity and lipophilicity of the carrier oil can influence how quickly the depot disperses and how rapidly the ester enters the bloodstream. Thinner oils like MCT tend to disperse more quickly, which may produce slightly higher peaks and slightly shorter effective duration compared to thicker oils like cottonseed. Hemi Pharma Testosterone Cypionate 200mg uses a carrier oil formulation designed for smooth injection and consistent absorption, with every batch verified by Janoshik Analytical third-party testing.

Albumin and SHBG Levels

Once testosterone is released from the ester and enters the bloodstream, it binds to proteins, primarily sex hormone-binding globulin (SHBG) and albumin. The Bi et al. (2018) PK model identified albumin as a significant covariate for testosterone clearance. Men with lower albumin levels (for example, due to liver disease or malnutrition) may clear testosterone differently, although for most healthy men this is not a major practical concern. SHBG levels are more clinically relevant: men with high SHBG bind more of their total testosterone, reducing the free (bioactive) fraction. This does not change the half-life of the cypionate ester, but it does change how much functional testosterone you get from each dose, which can influence the subjective experience and the need for dose adjustment.

How Does Understanding Half-Life Help You Optimise Your Protocol?

Grasping the testosterone cypionate half-life transforms your approach from guesswork to informed decision-making. Here is what it enables you to do:

First, it allows you to predict steady-state timing. On a consistent weekly injection protocol, steady state is typically reached after 4 to 5 half-lives. For testosterone cypionate, that means approximately 32 to 40 days (4 to 5 weeks) of consistent dosing. Any blood work drawn before this point does not reflect your true stable levels and should not be used as a basis for dose changes. Patience during this initial period is essential, as discussed in the testosterone cypionate week-by-week timeline.

Second, it lets you calculate washout periods. If you need to stop testosterone cypionate for any reason (fertility preservation, pre-surgery requirements, switching compounds), the 8-day half-life tells you that meaningful clearance takes roughly 5 to 6 weeks. Using HCG during this washout period can help maintain testicular function and ease the transition to post-cycle recovery.

Third, it provides the pharmacological basis for discussing frequency changes with your prescriber. If you are experiencing symptoms consistent with peak-and-trough fluctuations, such as feeling great for a few days then crashing, you now have the scientific reasoning to advocate for more frequent, smaller doses rather than simply accepting a fortnightly schedule. The evidence supports this approach. The guide on talking to your GP about testosterone cypionate covers how to frame this conversation productively.

Frequently Asked Questions

What is the exact half-life of testosterone cypionate?

The FDA-approved prescribing information for Depo-Testosterone states that the half-life of testosterone cypionate when injected intramuscularly is approximately 8 days. Published pharmacokinetic studies have reported values ranging from 7 to 8 days, with individual variation depending on body composition, injection site, and metabolic factors. For practical protocol planning, 8 days is the standard figure used by clinicians.

How long after my last testosterone cypionate injection will it be fully out of my system?

Complete elimination to negligible serum levels takes approximately 5 to 6 half-lives, which equates to 40 to 48 days after the final injection. However, trace amounts may be detectable in urine for longer periods depending on the sensitivity of the assay. For PCT timing, most protocols recommend starting SERMs approximately 2 weeks (roughly 2 half-lives) after the last injection of testosterone cypionate, when levels have dropped sufficiently to allow HPT axis recovery to begin.

Is the testosterone cypionate half-life different from testosterone enanthate?

Yes, but the difference is smaller than many online sources suggest. Testosterone cypionate has a half-life of approximately 8 days, while testosterone enanthate is typically reported at 4.5 to 7 days. The one-carbon difference in their ester chains produces a modest pharmacokinetic difference. In clinical practice, the two esters are considered interchangeable at equivalent doses and injection frequencies. You can read the detailed testosterone enanthate versus testosterone cypionate comparison for a full breakdown.

Can I inject testosterone cypionate every two weeks because of its long half-life?

You can, but the pharmacokinetics argue against it for most people. By day 14, only about 25% of the original dose remains, meaning your trough levels will likely fall below the therapeutic range. A comparative study of 263 men found that 200mg every 14 days produced significantly higher rates of erythrocytosis (7.8% vs 1.0%) compared to 100mg weekly, despite delivering the same total monthly dose. Weekly injection is the minimum frequency recommended by most modern TRT guidelines for testosterone cypionate.

Does the testosterone cypionate half-life change with higher doses?

The elimination half-life itself does not change with dose, because testosterone cypionate follows first-order (linear) elimination kinetics. This means the same proportion of the drug is cleared per unit of time regardless of the amount present. However, higher doses produce higher peak concentrations, which take longer to fall below a given threshold in absolute terms. A 400mg injection will maintain supraphysiological levels for longer than a 100mg injection, even though both follow the same 8-day half-life curve.

References

Bi, Y., Perry, P.J., Ellerby, M. and Murry, D.J. (2018) ‘Population Pharmacokinetic/Pharmacodynamic Modeling of Depot Testosterone Cypionate in Healthy Male Subjects’, CPT: Pharmacometrics and Systems Pharmacology, 7(4), pp. 259-268. Available at: https://pubmed.ncbi.nlm.nih.gov/29436172/ (Accessed: 5 November 2026).

El-Khatib, F.M., Osman, M.M., Huynh, L.M., Dianatnejad, S., Wu, Q. and Yafi, F.A. (2022) ‘Comparative assessment of outcomes and adverse effects using two different intramuscular testosterone therapy regimens: 100 mg IM weekly or 200 mg IM biweekly’, International Journal of Impotence Research, 34(6), pp. 558-563. Available at: https://pubmed.ncbi.nlm.nih.gov/34257404/ (Accessed: 5 November 2026).

McFarland, J., Craig, W., Clarke, N.J. and Spratt, D.I. (2017) ‘Serum Testosterone Concentrations Remain Stable Between Injections in Patients Receiving Subcutaneous Testosterone’, Drug Design, Development and Therapy, 11, pp. 2663-2667. Available at: https://pubmed.ncbi.nlm.nih.gov/29264562/ (Accessed: 5 November 2026).

Spratt, D.I., Stewart, I.I., Engert, M., Bagot, C. and McAdam, B. (2017) ‘Subcutaneous Injection of Testosterone Is an Effective and Preferred Alternative to Intramuscular Injection: Demonstration in Female-to-Male Transgender Patients’, Journal of Clinical Endocrinology and Metabolism, 102(7), pp. 2349-2355. Available at: https://pubmed.ncbi.nlm.nih.gov/28379417/ (Accessed: 5 November 2026).

Hackett, G., Kirby, M., Edwards, D., Jones, T.H., Wylie, K., Ossei-Gerning, N., David, J. and Muneer, A. (2023) ‘The British Society for Sexual Medicine Guidelines on Male Adult Testosterone Deficiency, with Statements for Practice’, World Journal of Men’s Health, 41(3), pp. 508-537. Available at: https://pubmed.ncbi.nlm.nih.gov/36876744/ (Accessed: 5 November 2026).

Shopping Basket
Scroll to Top